Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic ...
In September, Replit completed a $250M funding round that gave it a $3B valuation. That round was led by Prysm Capital and ...
This approach allows developers to create applications through natural language conversations rather than traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback